Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy
- 8 August 2014
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (4) , 757-763
Abstract
5-fluorouracil (5-FU) competes with uracil (Ura) as a substrate for dihydropyrimidine dehydrogenase (DPD). Low DPD activity impairs breakdown of Ura to dihydrouracil (UH2) and is associated with toxicity during 5-FU-based chemotherapy. Calculation of the 5-FU dose is based on body surface area, and new tools are needed to individualize treatment. The aim of study was to measure Ura and UH2 in saliva of patients with colorectal cancer and relate levels to treatment-induced toxicity. Saliva was collected from 73 patients with stage III colorectal cancer prior to adjuvant 5-FU-based treatment. Ura and UH2 were analyzed by a column-switching HPLC method. Toxicity was evaluated before each treatment cycle and the highest grade was noted at end of treatment. Toxicity was more common and severe among women compared with men. The Ura and UH2 concentrations in saliva were 5.0 ± 6.8 and 5.0 ± 4.0 nmol/ml, respectively. The UH2/Ura ratio was lower in women compared with men (1.2 ± 1.0 and 2.2 ± 2.5, respectively, p = 0.0026). Patients who needed to reduce the drug dose during treatment (or terminate treatment) due to toxicity had a lower ratio (1.3 ± 0.85) compared to patients who completed treatment without dose reduction (4.1 ± 4.3, p < 0.0001). Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH2 levels prior to chemotherapeutical treatment. This information may be useful in order to predict and prevent occurrence of treatment-related toxicities which otherwise may limit drug administration.Keywords
This publication has 24 references indexed in Scilit:
- Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5‐fluorouracil–based chemotherapyCancer, 2011
- The Value of Dihydrouracil/Uracil Plasma Ratios in Predicting 5-Fluorouracil-Related Toxicity in Colorectal Cancer PatientsJournal of International Medical Research, 2010
- Differences in toxicity across gender in patients treated with chemoradiation for rectal cancerAustralasian Radiology, 2007
- 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiencyCancer Letters, 2007
- Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU‐related toxicityBritish Journal of Clinical Pharmacology, 2007
- The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]DihydrouracilClinical Cancer Research, 2006
- Differences in toxicity between men and women treated with 5‐fluorouracil therapy for colorectal carcinomaCancer, 2005
- Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug DevelopmentThe Oncologist, 2005
- Pharmacogenetics in Cancer TreatmentAnnual Review of Medicine, 2003
- Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancerEuropean Journal of Cancer, 1990